Skip to main content

Meto vs Teladoc Health

A detailed head-to-head comparison of Meto and Teladoc Health — pricing, peptides, consultation models, and patient reviews.

At a Glance

RatingNo reviews
Starting PriceN/A
Peptides2
ConsultationHybrid
Lab TestingNo
Shipping3-5 business days

Pros

  • Insurance-first model.
  • Hybrid virtual and in-person care.
  • Specialist matching.
  • Broad metabolic health scope.
  • Physician leadership with relevant credentials.

Cons

  • No track record.
  • Self-pay pricing is opaque.
  • State availability is undisclosed.
  • Unknown support quality and response time.
  • Platform maturity unknown.
RatingNo reviews
Starting PriceN/A
Peptides2
ConsultationHybrid
Lab TestingNo
Shipping3-5 business days

Pros

  • Largest telehealth platform in the US with proven infrastructure and nationwide availability
  • Integrated chronic condition management
  • Brand-name GLP-1 medications and orforglipron available
  • Video consultations (not async-only)
  • Broadest insurance network in telehealth
  • Behavioral health integration

Cons

  • Weight management program launched in 2024
  • Providers are general practitioners, not obesity medicine specialists
  • Combined membership and medication cost is high ($224/mo for orforglipron) compared to focused competitors
  • Weight loss is one of many services, not the primary focus
  • Mixed patient satisfaction reviews for the weight management program specifically
  • No tirzepatide cash-pay option currently listed

Pros & Cons

Peptide Pricing Comparison

PeptideMetoTeladoc Health
SemaglutidePrice unavailablePrice unavailable
TirzepatidePrice unavailablePrice unavailable

Frequently Asked Questions

Is Meto or Teladoc Health better?

Meto offers 2 peptides and hybrid consultations. Teladoc Health offers 2 peptides and hybrid consultations. The best choice depends on which peptides you need, your budget, and preferred consultation model.

Which is cheaper, Meto or Teladoc Health?

See the pricing table above for a detailed comparison.